Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.